NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
08:54
The Annual Meeting of Romanian Diplomacy starts today. Security, the EU, and the war in the East are the main topics on the event's agenda.
08:30
Interim Minister of Defense, Radu Miruță: "A new government is needed, a government with full powers."
08:25
PSD leaders meet in Sinaia, a day before the start of the autumn parliamentary session / Agenda of discussions
08:07
Serghei Lavrov warns that NATO's activity in the Arctic represents a direct threat to Russia's security: "The risk of incidents is increasing."
07:52
Interim Minister of Defense, Radu Miruță: "I cannot be disappointed, as Minister of Defense, by the President of Romania. I would like the point to be made more concretely regarding those who are guilty."
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
